The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Thiazolidinediones and Heart Failure
Abstract
OBJECTIVE—Thiazolidinediones (TZDs) are known to increase the risk of heart failure in patients with type 2 diabetes. We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system. RESEARCH DESIGN AND METHODS—Evidence from randomized trials, controlled observational studies, anecdotal case reports, case series, and spontaneous reports in the Canadian Drug Reaction Monitoring Program (CADRMP) was analyzed in a teleo-analysis. RESULTS—A random-effects meta-analysis of three randomized controlled trials showed an odds ratio (OR) of 2.1 (95% CI 1.08–4.08; P = 0.03) for the risk of heart failure in patients randomized to TZDs compared with placebo. Four observational studies revealed an OR of 1.55 (1.33–1.80; P < 0.00001) for heart failure with TZDs. A dose-time-susceptibility analysis of 28 published reports and 214 spontaneous reports from the CADRMP database showed that heart failure was more likely to occur after several months (with median treatment duration of 24 weeks after initiation of therapy). Heart failure equally occurred at high and low doses. The adverse reaction was not limited to the elderly, with 42 of 162 (26%) of the reported cases occurring in patients aged <60 years. CONCLUSIONS—Our teleo-analysis confirms the increased magnitude of the risk of heart failure with TZDs. We estimate the number needed to harm with TZDs to be ∼50 over 2.2 years. Existing guidelines and package inserts may have to be revised to incorporate these risk characteristics of TZDs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most common adverse effects with TZDs are weight gain and fluid retention, with peripheral edema and a twofold increased risk for congestive heart failure (61,62).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [62]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic Control and Heart Failure Among Adult Patients With Diabetes
Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A. M., Liu, J. Y., Sidney, S., & Selby, J. V. (2001) · Circulation · doi:10.1161/01.cir.103.22.2668 · Cited by 709
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 314
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 298
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramı́rez, G., & DeFronzo, R. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Sutton, M. S. J., Rendell, M., Dandona, P., Dole, J., Murphy, K., Patwardhan, R., Patel, J., & Freed, M. I. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2058 · Cited by 254
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Mudaliar, S. R. D., Chang, A. R., & Henry, R. R. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.406 · Cited by 209
Tang, W. H. W., Francis, G. S., Hoogwerf, B. J., & Young, J. B. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00159-1 · Cited by 150
Thiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema
Kermani, A., & Garg, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.9.1088 · Cited by 115
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction
Inzucchi, S. E., Masoudi, F. A., Wang, Y., Kosiborod, M., Foody, J. M., Setaro, J. F., Havranek, E. P., & Krumholz, H. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1680 · Cited by 101
Thiazolidinediones and the risk of edema: A meta-analysis
Berlie, H. D., Kalus, J. S., & Jaber, L. A. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.010 · Cited by 100
Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention
Karalliedde, J. J., Buckingham, R. E., Starkie, M., Lorand, D., Stewart, M. W., & Viberti, G. C. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060606 · Cited by 97
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
Karter, A., Ahmed, A., Liu, J., Moffet, H. M., & Parker, M. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01704.x · Cited by 90
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060.pub2 · Cited by 87
Maru, S., Koch, G. G., Stender, M., Clark, D., Gibowski, L., Petri, H., White, A., & Simpson, R. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.20 · Cited by 86
Pulmonary Edema Associated with Rosiglitazone and Troglitazone
Thomas, M. L., & Lloyd, S. J. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.10132 · Cited by 78
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Wooltorton, E. (2002) · PubMed Central · Cited by 50
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzales, F., & Yang, T. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090935 · Cited by 50
Teleoanalysis: combining data from different types of study
Wald, N. J., & Morris, J. K. (2003) · BMJ · doi:10.1136/bmj.327.7415.616 · Cited by 49
RAJAGOPALAN, R., Rosenson, R. S., FERNANDES, A., Khan, M. A., & MURRAY, F. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.016 · Cited by 48
Thiazolidinedione-Induced Congestive Heart Failure
CHENG, A. Y. Y., & Fantus, I. G. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d400 · Cited by 46
Hartung, D. M., Touchette, D. R., Bultemeier, N. C., & Haxby, D. G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1329 · Cited by 39
Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review
Page, R. L., II, Gozansky, W. S., & Ruscin, J. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.945.32721 · Cited by 34
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060 · Cited by 33
Pioglitazone-induced heart failure despite normal left ventricular function
Shah, M., Kolandaivelu, A., & Fearon, W. F. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.10.010 · Cited by 15
Thiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema
Jamieson, A., & Abousleiman, Y. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.4.571 · Cited by 7
Thiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema: In Response
Kermani, A., & Garg, A. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.4.575 · Cited by 2
Cited by
Sorted by citations
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Self-citation
Metadata
- Authors
- Singh, S., Loke, Y. K., & Furberg, C. D.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- University of East Anglia (GB)
- Wake Forest University Health Sciences (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-08-01
- Volume
- 30
- Issue
- 8
- Pages
- 2148-2153
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1979369530
- Cited by
- 262
- References
- 31
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 11 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 12 · 2015: 14 · 2014: 15 · 2013: 19 · 2012: 18
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- thiazolidinediones, heart failure, type 2 diabetes, adverse drug reactions, number needed to harm, drug safety, spontaneous adverse drug reports, drug labeling revision
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Susceptibility, Heart Failure, Humans, Hypoglycemic Agents, Odds Ratio, Randomized Controlled Trials as Topic, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
